此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma

2011年7月11日 更新者:University Hospital, Ghent

This pilot study is a double-blinded, randomized controlled, two-centre trial in which subjects will receive 4 to 8 (subcutaneous administered) doses of medication (Omalizumab or placebo) (dose and dosing interval calculated on body weight and baseline total serum IgE). During the treatment period and follow-up, the clinical efficacy of the treatment will be assessed by evaluation of symptoms, Quality of Life questionnaire, morning Peak Expiratory Flow measurement, smell test, nasal endoscopy, CT-scan, peak nasal inspiratory flow and spirometry. Biological activity will be evaluated by measuring peripheral and local (in serum, in nasal secretions, biopsies) markers of inflammation.

Study hypothesis

  1. Evaluation of the efficacy and safety of anti-IgE (Omalizumab) in patients with nasal polyposis and comorbid asthma.
  2. Exploration of anti-IgE effects on local and systemic metabolism of IgE in nasal polyposis
  3. Clinical assessment of the IgE theory in the pathogenesis of nasal polyps

研究概览

研究类型

介入性

注册 (实际的)

23

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Ghent、比利时、9000
        • University Hospital, Ghent
      • Leuven、比利时、3000
        • UZ Gasthuisberg

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Subjects must be at least 18 years of age, of either gender and any race.
  • Subjects must have a diagnosis of bilateral nasal polyps at screening and baseline that have recurred after surgical resection or nasal polyps that are grades 3 or 4 in both nares using the scoring system described in table 5. Bilateral nasal polyposis is defined as sinus symptoms for more than 3 months, bilateral opacity on CT-scan imaging and visible nasal polyps at endoscopy.

Subjects must have a diagnosis of asthma for more than 2 years. Subjects must be in good health, free of any clinically significant disease that would interfere with the study schedule or procedures or compromise his/her safety.

  • Subjects must be willing to give informed consent and adhere to visit schedules, medication restrictions, and agree to perform daily diary entries.
  • Subjects must be free of any upper respiratory tract infection within two weeks prior to inclusion.
  • Clinical laboratory tests must be within normal limits or clinically acceptable for the investigator.
  • Non-pregnant women of childbearing potential must use a medically acceptable, adequate form of birth control. This includes: a) hormonal contraceptive as prescribed by a physician (eg, oral combined, hormonal implant, depot injectable); b) medically prescribed Intra-Uterine Device (IUD); c) condom in combination with a spermicide; d) monogamous relationship with a male partner who has had a vasectomy or is using a condom plus spermicide during the study. They must have started this birth control method at least three months prior to screening (with the exception of condom in combination with a spermicide), and they must agree to continue its use for at least 3 months after last dosing. Women of childbearing potential who are not currently sexually active must agree and consent to using a double-barrier method should they become sexually active during the course of this study. Women who are surgically sterilized or are at least one year postmenopausal are considered not to be of childbearing potential. However, all female subjects must have a urine pregnancy test prior to treatment, which must be negative. A monthly-control pregnancy test is requested.
  • Male subjects must agree to use an adequate form of birth control from first dosing to at least 3 months after last dosing. They must either agree to use a condom with spermicide or agree to have sexual relations only with women using medically acceptable forms of birth control as described above.

Exclusion Criteria:

  • Women must not be pregnant, breast feeding, or premenarcheal.
  • Patients younger than 18 years old.
  • Subjects with history of systemic reactions to the study medication.
  • Subjects with prohibited medication at screening without full wash-out period.
  • Subjects with acute sinusitis, concurrent nasal infection, or subjects who have had a nasal or upper respiratory tract infection within two weeks of the inclusion are excluded.
  • Subjects with cystic fibrosis, primary ciliary's dysfunction or Kartagener's syndrome by history are excluded.
  • Subjects must not have ever been diagnosed with a parasitic infection.
  • Subjects must not have ever been diagnosed with cancer
  • Subjects must not have a medical history of Human Immunodeficiency Virus (HIV) or hepatitis B or C. Testing will not be done at screening.
  • Subjects must not have had an acute asthmatic attack requiring admission to a hospital (excluding emergency room visits which resulted in direct discharge without hospitalization) within the four weeks prior to screening.
  • Subjects must not have received specific immunotherapy within the previous three months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂
安慰剂
有源比较器:奥马珠单抗

Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.

Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Effect of Omalizumab on nasal polyp size and evolution of nasal polyps
大体时间:At every study visit starting from week 0 until week 20
Nasal examination at all visits by endoscopy of each nasal fossa. Polyps will be graded by the Modified DAVOS score
At every study visit starting from week 0 until week 20

次要结果测量

结果测量
措施说明
大体时间
Effect of Omalizumab on rhinosinusitis symptoms:nasal discharge, nasal congestion, postnasal drip scores: Subject's Diary
大体时间:At screening visit, baseline visit and at week 0, 4, 8, 12, 16, 20
Dispense / collect / review diary
At screening visit, baseline visit and at week 0, 4, 8, 12, 16, 20
Effect of Omalizumab on asthma symptom scores including cough, wheeze, dyspnoea: Subject's Diary.
大体时间:At screening visit, baseline visit and at week 0, 4, 8, 12, 16, 20
Dispense / collect / review diary
At screening visit, baseline visit and at week 0, 4, 8, 12, 16, 20
Effect of Omalizumab on sinus computed tomography (CT)-scan score : Sinus CT-scan evaluation
大体时间:Visit before dosing and at week 16
Sinus CT-scan evaluation
Visit before dosing and at week 16
Effect of Omalizumab on smell: UPSIT (University of Pennsylvania Smell Identification Test)
大体时间:Baseline visit and at week 10
Olfactory test
Baseline visit and at week 10
Effect of Omalizumab on Rhinitis specific Quality of Life: Rhinosinusitis Outcome Measure (RSOM-31)
大体时间:At baseline visit
At baseline visit
Effect of Omalizumab on asthma related Quality of life: Asthma Quality of Life Questionnaire (AQLQ)
大体时间:At baseline visit
At baseline visit
Effect of Omalizumab on overall Quality of Life: The Short Form (36) Health Survey (SF-36)
大体时间:At baseline visit
At baseline visit
Effect of Omalizumab on peak nasal inspiratory flow
大体时间:On screening visit, baseline visit and on week 4,8,12, 16 and 20
On screening visit, baseline visit and on week 4,8,12, 16 and 20
Effect of Omalizumab and Forced Expiratory Volume in 1 second (FEV1): spirometry
大体时间:At screening visit, baseline visit and week 16 and 20
At screening visit, baseline visit and week 16 and 20
Effect of Omalizumab on diverse inflammatory mediators in serum, in nasal fluid (eosinophilic cationic protein (ECP), Interleukin-2 receptor (IL-2R), Sol Interleukin-5 receptor, soluble Cluster of differentiation 23 (sCD23), tryptase)
大体时间:At screening visit, baseline visit and week 4, 8, 12, 16 and 20
At screening visit, baseline visit and week 4, 8, 12, 16 and 20
Evaluation of adverse events, directly or by general physical examination, blood sampling , review of concomitant medication or symptom scores.
大体时间:week 2, 4, 6, 8, 10, 12, 14, 16, 20
week 2, 4, 6, 8, 10, 12, 14, 16, 20

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Paul Van Cauwenberge, PhD, MD、University Hospital, Ghent, Belgium

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2006年12月1日

初级完成 (实际的)

2008年10月1日

研究完成 (实际的)

2009年12月1日

研究注册日期

首次提交

2011年7月7日

首先提交符合 QC 标准的

2011年7月11日

首次发布 (估计)

2011年7月13日

研究记录更新

最后更新发布 (估计)

2011年7月13日

上次提交的符合 QC 标准的更新

2011年7月11日

最后验证

2011年7月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅